Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry

BACKGROUND: Despite the advances of potent oral P2Y(12) inhibitors, their onset of action is delayed, which might have a negative impact on clinical outcome in patients undergoing percutaneous coronary intervention (PCI). Trials conducted in the United States of America have identified cangrelor as...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:BMC Cardiovasc Disord
मुख्य लेखकों: Selvarajah, A., Tavenier, A. H., Bor, W. L., Houben, V., Rasoul, S., Kaplan, E., Teeuwen, K., Hofma, S. H., Lipsic, E., Amoroso, G., van Leeuwen, M. A. H., Berg, J. M. ten, van ‘t Hof, A. W. J., Hermanides, R. S.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2021
विषय:
Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8199523/
https://ncbi.nlm.nih.gov/pubmed/34118880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12872-021-02093-4
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन